• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies

    10/27/25 8:40:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUPR alert in real time by email

    SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions Pte Ltd (SBS), a treater and disposer of bio-medical waste, to explore the integration of Cuprina's medical waste recycling technology into SBS's existing waste management facility in Singapore.

    The collaboration aims to develop an integrated process that will further reduce reliance on incineration and landfilling, enhance recycling efficiency, unlock new revenue streams from recycled materials, and position the companies and Singapore as leaders in sustainable waste management.

    Pursuant to the MOU, Cuprina will provide technical expertise, training, and support for this exploration, which will take the form of a feasibility study and pilot program at SBS's facility. During this period, Cuprina will leverage its exclusive Southeast Asia licensing rights to a high-temperature steam process known as autoclaving to sterilize, decontaminate, and recycle plastic-based medical waste into high-value resins. This technology is the first of its kind developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and Global Environment Facility (GEF), which work together to fund global environmental goals.

    As per the MOU, SBS will contribute the operational data, facility access, and regulatory support necessary to facilitate integration of the companies'  combined waste recycling process with Singapore's environmental standards, and to secure compliance with Singapore authorities such as the National Environment Agency and Ministry of Health.

    Together, the companies will seek to develop revenue-sharing models for the integrated process and explore expansion opportunities for the technology across Southeast Asia;

    "We are excited to sign this MOU, representing Cuprina's first potential commercialization of our recently licensed medical waste recycling technology," said Cuprina CEO, David Quek Yong Qi. "We are optimistic that this technology, developed and tested over 20 years with UNIDO and GEF, will integrate superbly with SBS' waste management processes. We look forward to working with SBS on our pilot program and arriving at a definitive agreement in the near future."

    Mr. Quek said he believed the companies' integrated recycling technology could obtain all necessary Singapore regulatory approvals and commence operations by the end of 2026.

    SBS Managing Director, Selva Kumar added, "We are thrilled to collaborate with Cuprina on this innovative approach to waste management. Integrating their technology into our processes will, we believe,  help us meet evolving environmental regulations and contribute to a circular economy in Singapore and beyond."

    About Cuprina Holdings (Cayman) Limited

    We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards.

    For more information, please visit

    About Singapore Biowaste Solutions Pte Ltd

    Singapore Biowaste Solutions Pte Ltd is Singapore's most advanced provider for bio-medical waste disposal and management. The company offers state-of-the art technologies, a highly trained team of operational experts, advanced facilities, and unwavering commitment to the needs of its clients.

    FORWARD-LOOKING STATEMENTS

    Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

    Cuprina Holdings (Cayman) Limited Investor Contact:

    Investor Relations

    c/o Blk 1090 Lower Delta Road #06-08

    Singapore 169201

    +65 8512 7275

    Email: [email protected]

    Investor Relations Inquiries:

    Skyline Corporate Communications Group, LLC

    Scott Powell, President

    1177 Avenue of the Americas, 5th Floor

    New York, New York 10036

    Office: (646) 893-5835

    Email: [email protected]



    Primary Logo

    Get the next $CUPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CUPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board

    SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Regulatory Milestone in Saudi Arabia Cuprina's 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority (SFDA) for MEDIFLY, the Company's medical-grade maggot debridemen

    3/11/26 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth

    SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi. Diversification

    12/9/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

    SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina's closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), th

    11/28/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    SEC Filings

    View All

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    3/11/26 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    12/9/25 8:25:53 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/28/25 8:30:31 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    Leadership Updates

    Live Leadership Updates

    View All

    Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market

    SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025. Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first

    7/21/25 9:00:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care